| Literature DB >> 30618075 |
Huijuan Feng1, Juqing Wu1, Pan Chen1, Jing Wang1, Yuying Deng1, Guoquan Zhu1, Jialang Xian1, Liuhua Huang1, Wei Ouyang1.
Abstract
Cardiac hypertrophy is a myocardial enlargement due to overload pressure, and the primary cause of heart failure. We investigated the function of miR-375-3p in cardiac hypertrophy and its regulating mechanisms. miR-375-3p was upregulated in hearts of the transverse aortic constriction rat model and angiotensin II (Ang II)-induced primary cardiomyocyte hypertrophy model; the opposite was observed for lactate dehydrogenase B (LDHB) protein expression. miR-375-3p knockdown reduced the surface area of primary cardiomyocytes increased by Ang II treatment and decreased the B-natriuretic peptide (BNP) and β-myosin heavy chain (β-MHC) messenger RNA (mRNA) and protein levels. miR-375-3p was also observed to directly target LDHB. LDHB knockdown increased the surface area of Ang II-treated primary cardiomyocytes and increased the BNP and β-MHC mRNA and protein levels. LDHB knockdown attenuated the effects of miR-375-3p on the surface area of primary cardiomyocytes and BNP and β-MHC levels. Therefore, miR-375-3p inhibitor suppresses Ang II-induced cardiomyocyte hypertrophy by promoting LDHB expression.Entities:
Keywords: cardiac hypertrophy; lactate dehydrogenase B; miR-375-3p
Mesh:
Substances:
Year: 2019 PMID: 30618075 DOI: 10.1002/jcp.28116
Source DB: PubMed Journal: J Cell Physiol ISSN: 0021-9541 Impact factor: 6.384